Healthy Extracts Inc.’s (HYEX) “Live Life Young Again” Strategy Reflects The Company’s Continued Optimism For 2021

• Healthy Extracts Inc. recently declared its 2020 Q4 results, with revenue growth at 71% over the previous year
• The company’s 2021 strategy “Live Life Young Again” aligns with its plant-based product range and its overall confidence for 2021
• Results of the clinical studies of the Fuel4Thought Brain Booster product were published in the renowned World Journal of Advanced Research and Reviews

Healthy Extracts (OTCQB: HYEX), is engaged in the research, development, and sale of natural plant-based products that concentrate on nerve and heart health. The company’s growth and expansion are evident in the company’s robust 2020 Q4 results. Their latest financial report highlights the revenue increase of 71% at $1,276,559 compared to 2019 revenues of $748,377. The plant-based food industry is expected to reach a value of $74.2 billion in 2027, guided by a CAGR of 11.9% from 2020 to 2027 (https://ibn.fm/qeyzR).

Duke Pitts, president of Healthy Extracts Inc., stated that the 2020 results reflected the upward momentum of the company. The company recently changed its name from Grey Cloak Tech Inc. to Healthy Extracts, Inc., better aligned with the company’s objectives. Healthy Extracts is geared towards 2021 with its “Live Life Young Again” strategy.

Some key highlights of 2020 include:

• Gross revenue recording an increase of 71% in 2020, despite the COVID situation
• Healthy Extracts Inc. (HYEX) name change from Grey Cloak Tech with full reporting and move up to the OTCQB
• The company’s elimination of all convertible debt
• Net shareholder equity increase of $3.7 million
• Collaboration with Ultimate Brain Nutrients, a science-based company that has six patents (2 issued, 4 pending) and proprietary formulations
• Introduction of Clinical Immune, a clinically proven immunity product focusing on heart and respiratory immune health
• Sales of Fuel4Thought Brain Booster product to begin in Q2 after completion of key clinical studies
• Launch of HerHeart, the only cardiovascular product for women, with positive clinical trial results published in Annals of Women’s Health (https://ibn.fm/DVasH)

The company is making remarkable strides to strengthen its market positions in the plant-based health industry through its two key subsidiaries, the science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”).

For more information, visit the company’s website at www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.